Icariin inhibits foam cell formation by down-regulating the expression of CD36 and up-regulating the expression of SR-BI.
Icariin is an important pharmacologically active flavonol diglycoside that can inhibit inflammation in lipopolysaccharide (LPS)-stimulated macrophages. However, little is known about the molecular mechanisms underlying the inhibitory effect of Icariin in the formation of foam cells. In this study, macrophages were cultured with LPS and oxidized low-density lipoprotein (oxLDL) in the presence or absence of Icariin. RT-PCR and western blot were used to detect the levels of mRNA and protein expression of CD36, scavenger receptor class B type I (SR-BI) and the phosphorylation of p38MAPK. It was demonstrated that 4 µM or 20 µM Icariin treatment significantly inhibited the cholesterol ester (CE)/total cholesterol (TC) and oxLDL-mediated foam cell formation (P < 0.05). The binding of oxLDL to LPS-activated macrophages was also significantly hindered by Icariin (P < 0.05). Furthermore, Icariin down-regulated the expression of CD36 in LPS-activated macrophages in a dose-dependent manner and CD36 over-expression restored the inhibitory effect of Icariin on foam cell formation. The phosphorylation of p38MAPK was reduced by Icariin, indicating that Icariin reduced the expression of CD36 through the p38MAPK pathway. In addition, Icariin up-regulated SR-BI protein expression in a dose-dependent manner, and SR-BI gene silencing restored the inhibitory effect of Icariin on foam cell formation. These data demonstrate that Icariin inhibited foam cell formation by down-regulating the expression of CD36 and up-regulating the expression of SR-BI. Therefore, our findings provide a new explanation as to why Icariin could inhibit atherosclerosis.
Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Haitao
H
Yang
Lijie
L
Yan
Peng
P
Qian
Hongyan
H
Duan
Jintao
J
Wu
Bing
B
Li
Shanling
S
Wang
D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D050197:Atherosclerosis / Q000188:drug therapy; D018955:CD36 Antigens / Q000235:genetics / Q000378:metabolism*; D018929:Cell Culture Techniques; D002460:Cell Line; D005419:Flavonoids / Q000494:pharmacology*; D005487:Foam Cells / Q000187:drug effects* / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000494:pharmacology; D020935:MAP Kinase Signaling System / Q000187:drug effects; D051122:Scavenger Receptors, Class B / Q000235:genetics / Q000378:metabolism*
D000893:Anti-Inflammatory Agents; D018955:CD36 Antigens; D005419:Flavonoids; D008070:Lipopolysaccharides; D008077:Lipoproteins, LDL; C495124:SCARB1 protein, human; D051122:Scavenger Receptors, Class B; C099252:oxidized low density lipoprotein; C056599:icariin
ATHEROSCLEROSIS; CD36; FOAM CELL; ICARIIN; SCAVENGER RECEPTOR CLASS B TYPE I